Anpac Bio-Medical Science Co., Ltd., a Chinese developer of a cancer screening platform, raised over $2m in Series B funding.
Backers included Shanghai Zhangjiang Science & Technology Investment Corporation, as well as private investors related to the insurance industry.
The company intends to use the funds to advance its “Cancer Differentiation Analysis” (CDA) technology.
Led by Chief Executive Officer Dr. Chris Yu, Anpac develops proprietary CDA technology that enables cancer screening and early detection by analyzing standard, non-invasive “Blood Biopsies”. The company has collaborations and partnerships with nearly 140 cooperative medical institutions.
As a result of the investment, Anpac is now establishing a U.S. Headquarters.